Laboratory medicine · 2025
Serologic detection of regenerating protein I alpha by time-resolved fluoroimmunoassay and its clinical value in gastric cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiang Zhongyi, Wang Xiaoyan, Zhu Akao, Chen Xindong, Qin Yuan, Zhou Xiumei, Zhao Xueqin, Wang Yigang, Huang Biao, Fang Hongming, Liu Pengfei
Аннотация
BACKGROUND: Regenerating protein I alpha (REG Iα) plays a key role in the progression of gastric cancer (GC). However, the clinical application value of serum REG Iα in GC remains largely unknown.
METHODS: Serum REG Iα levels were analyzed through time-resolved fluoroimmunoassay (TRFIA) in healthy controls (HCs) and patients with benign gastric disease (BGD) and GC.
RESULTS: The REG Iα levels of patients with GC were significantly higher than those of HCs and patients with BGD (P < .0001). The REG Iα levels were higher in patients with GC with poor pathological differentiation type; tumor, node, and metastasis stages III-IV; deep tumor invasion (T3-T4); and distant metastasis (P < .05). The diagnostic efficiency of the combined REG Iα, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) tests improved compared with that of the single-indicator test for the diagnosis of patients with GC.
CONCLUSION: REG Iα-TRFIA may facilitate the ancillary diagnosis of GC and have a monitoring role for further progression of GC. It can also help elucidate the possible diagnostic role of serum REG Iα as a noninvasive tool.
METHODS: Serum REG Iα levels were analyzed through time-resolved fluoroimmunoassay (TRFIA) in healthy controls (HCs) and patients with benign gastric disease (BGD) and GC.
RESULTS: The REG Iα levels of patients with GC were significantly higher than those of HCs and patients with BGD (P < .0001). The REG Iα levels were higher in patients with GC with poor pathological differentiation type; tumor, node, and metastasis stages III-IV; deep tumor invasion (T3-T4); and distant metastasis (P < .05). The diagnostic efficiency of the combined REG Iα, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) tests improved compared with that of the single-indicator test for the diagnosis of patients with GC.
CONCLUSION: REG Iα-TRFIA may facilitate the ancillary diagnosis of GC and have a monitoring role for further progression of GC. It can also help elucidate the possible diagnostic role of serum REG Iα as a noninvasive tool.